SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?


To: Daniel Kahn who wrote (705)4/11/1999 2:26:00 PM
From: Ibexx  Respond to of 942
 
Daniel,

It's my personal opinion that market has not fully factored the Agouron deal into WLA's stock price. It will happen when they see the accretive earnings realized--in black and white--as smaller biotechs could also be a serious cash burn despite their R&D contributions.

As I posted before on this thread, the Agouron acquisition is one smart move made by WLA management.

Regards,
Ibexx